Health Care & Life Sciences » Pharmaceuticals | Sareum Holdings PLC

Sareum Holdings PLC | Balance Sheet

Fiscal year is July-June. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
421.60
900.60
1,480.00
1,252.60
2,305.50
1,375.30
Total Accounts Receivable
61.90
82.20
196.90
170.00
128.70
278.70
Other Current Assets
35.60
93.80
40.70
64.10
-
112.70
Total Current Assets
519.00
1,076.60
1,717.70
1,486.70
2,434.20
1,766.70
Net Property, Plant & Equipment
-
4.90
3.10
1.30
13.30
8
Total Investments and Advances
-
706.80
209.80
475.00
53.60
41.40
Total Assets
519.00
1,788.30
1,930.60
1,963.10
2,501.10
1,816
Accounts Payable
54.80
38.20
35.50
72.20
-
Other Current Liabilities
25.20
27.60
31.90
27.40
155.50
Total Current Liabilities
79.90
65.80
67.40
99.60
155.50
Total Liabilities
79.90
65.80
67.40
99.60
155.50
Common Equity (Total)
439.10
1,722.50
1,863.20
1,863.50
2,345.60
Total Shareholders' Equity
439.10
1,722.50
1,863.20
1,863.50
2,345.60
Total Equity
439.10
1,722.50
1,863.20
1,863.50
2,345.60
Liabilities & Shareholders' Equity
519.00
1,788.30
1,930.60
1,963.10
2,501.10

About Sareum Holdings

View Profile
Address
Unit 2A, Langford Arch
Cambridge Cambridgeshire CB22 3FX
United Kingdom
Employees -
Website http://www.sareum.co.uk
Updated 07/08/2019
Sareum Holdings Plc engages in the discovery and development of drug candidates for the treatment of cancers and autoimmune diseases. Its drug discovery pipeline includes Chk1, TYK2, and Aurora+FLT3 kinases. The company was founded by Timothy John Mitchell, David Hugh Williams, and John Charles Reader on August 1, 2003 and is headquartered in Cambridge, the United Kingdom.